FOLH1 and prostate carcinoma: Pasotuxizumab is a PSMA/CD3-targeting BSAB, and preclinical studies have shown that pasotuxizumab induces T cells to lyse prostate cancer cells at a median effective concentration of 0.1–4 ng/ml, leading to delayed tumor growth, tumor shrinkage, and disease remission [198].